Αποτελέσματα Αναζήτησης
6 Ιαν 2023 · Today, the U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. Leqembi is the second of a new...
6 Δεκ 2021 · A new Cleveland Clinic-led study has identified sildenafil -- an FDA-approved therapy for erectile dysfunction (Viagra) and pulmonary hypertension (Ravatio) -- as a promising drug candidate to...
On June 7, 2021, the FDA gave Aducanumab expedited approval [FDA Approved Drug Products: Aduhelm (Aducanumab-avwa) Intravenous Injection]. Aducanumab (AduhelmTM) is an anti-amyloid antibody and is an intravenous (IV) infusion medication for AD. An FDA-approved diagnostic test is often recommended prior to the start of the therapy.
2 Ιουλ 2024 · The FDA approved Kisunla, known chemically as donanemab, based on results from an 18-month study in which patients given getting the treatment declined about 22% more slowly in terms of memory and cognitive ability than those who received a dummy infusion.
4 Οκτ 2022 · Results from the National Institutes of Health’s Drug Repurposing for Effective Alzheimer’s Medicines (DREAM) study show that sildenafil (Viagra) and tadalafil (Cialis) may not be suitable candidates for treating dementia.
5 Μαρ 2024 · Sildenafil is the main component of drugs used to treat erectile dysfunction (Viagra) and pulmonary arterial hypertension (Revatio). "Our findings provide further weight to re-purposing this...
6 Ιουλ 2023 · The first drug found to slow the progression of Alzheimer's disease has been granted full approval by the Food and Drug Administration.
